HempNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Enhances Life by Uniting Nature and Science

An ongoing concern in North America, as reported by the Centers for Disease Control and Prevention, is that Americans are only taking advantage of preventive medical services about half as often as they should. Endeavoring to become a pioneer in preventative medicine, health science company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) was founded on the belief that, in healthcare, prevention is the best policy, and that nature and science can unite to offer a range of innovative, untapped solutions to address unmet clinical needs. As quoted in a recent article: “PreveCeutical is taking a new look at ways to combat chronic health concerns such as diabetes and obesity, pain management, neurological disorders and cancer. PreveCeutical developed its CELLB9® oral dilute solution utilizing select peptides from the blue scorpion, which is found only in the Caribbean region. PreveCeutical’s “Nature Identical” research team is building on proprietary chemistry to produce controlled venom peptides that it hopes will be able to halt the progression of cancers, while also exploring the peptides’ potential in responding to other medical concerns related to metabolic disorders, pain, cardiovascular disease and infectious maladies.”

To view the full article, visit http://cnw.fm/h2FOV

About PreveCeutical Medical Inc.

PreveCeutical Medical Inc. is a health sciences company that develops innovative preventive therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster.  CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. For more information about PreveCeutical, visit www.PreveCeutical.com.

More from CannabisNewsBreaks

• HempNewsBreaks – Turning Point Brands Inc. (NYSE: TPB) Closes $300M Senior Secured Notes Offering 
• HempNewsBreaks – WEED Inc. (BUDZ) Announces 2024 Highlights, Plans to Expand into Consumer Packaged Goods
• HempNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Closes $3.6M Registered Direct

About HempWire

HempWire (HW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) HempNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. HW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, HW brings its clients unparalleled visibility, recognition and brand awareness. HW is where news, content and information converge.

For more information please visit https://www.hempwire.com

Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/disclaimer/

HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net